Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Molecular Templates recruits participants in phase I trial of MT-3724

Feb. 17, 2015

Advaxis and Incyte to evaluate combination of two novel cancer immunotherapies

Feb. 13, 2015

FDA advisory committees set date to jointly review talimogene laherparepvec BLA

Feb. 12, 2015

EMA grants orphan drug status to Theravectys vaccine for ATL/L

Feb. 9, 2015

New safety data on PAT-SM6 in multiple myeloma patients

Feb. 9, 2015

OncoMed begins dosing in phase II study of demcizumab in NSCLC

Feb. 6, 2015

Genmab reports data from phase II study of daratumumab in refractory multiple myeloma

Feb. 6, 2015

Symphogen regains rights to Sym-004 and focuses on oncology

Feb. 3, 2015

Valeant enters agreement to acquire Dendreon assets

Feb. 2, 2015

Celldex Therapeutics and BMS begin study of varlilumab and Opdivo

Jan. 30, 2015

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...